Paul Tudor Jones Incyte Corp Transaction History

Tudor Investment Corp Et Al

$25.1 Billion
Q4 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Incyte Corp stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 92,915 shares of INCY stock, worth $6.7 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

92,915

Previous 27,474 238.19%

Holding current value

$6.7 Million

Previous $1.82 Million 253.36%

% of portfolio

0.03%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$65.08 - $83.38 $4.26 Million - $5.46 Million	65,441 Added 238.19%	92,915 $6.42 Million
Q3 2024 Nov 14, 2024	BUY	$57.33 - $68.61 $354,643 - $424,421	6,186 Added 29.06%	27,474 $1.82 Million
Q2 2024 Aug 14, 2024	BUY	$51.18 - $63.75 $773,125 - $963,007	15,106 Added 244.35%	21,288 $1.29 Million
Q1 2024 May 15, 2024	BUY	$56.55 - $66.59 $349,592 - $411,659	6,182 New	6,182 $352,000
Q3 2023 Nov 15, 2023	BUY	$57.77 - $65.93 $175,274 - $200,031	3,034 Added 2.65%	117,564 $6.79 Million
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $152,009 - $188,321	2,494 Added 2.23%	114,530 $7.13 Million
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $7.87 Million - $9.64 Million	112,036 New	112,036 $8.1 Million
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $1.52 Million - $1.9 Million	22,970 Added 777.59%	25,924 $1.73 Million
Q2 2022 Aug 15, 2022	BUY	$66.18 - $83.18 $195,495 - $245,713	2,954 New	2,954 $224,000
Q1 2022 May 16, 2022	SELL	$66.02 - $79.71 $1.78 Million - $2.14 Million	-26,896 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$63.34 - $74.11 $1.97 Million - $2.31 Million	-31,170 Reduced 53.68%	26,896 $1.97 Million
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $3.67 Million - $4.49 Million	53,392 Added 1142.32%	58,066 $3.99 Million
Q2 2021 Aug 16, 2021	SELL	$79.87 - $87.53 $282,180 - $309,243	-3,533 Reduced 43.05%	4,674 $393,000
Q1 2021 May 17, 2021	SELL	$76.02 - $100.5 $4.41 Million - $5.83 Million	-58,049 Reduced 87.61%	8,207 $667,000
Q4 2020 Feb 16, 2021	BUY	$80.74 - $97.7 $2.98 Million - $3.61 Million	36,932 Added 125.94%	66,256 $5.76 Million
Q3 2020 Nov 16, 2020	BUY	$85.07 - $109.69 $1.35 Million - $1.74 Million	15,901 Added 118.46%	29,324 $2.63 Million
Q2 2020 Aug 14, 2020	BUY	$74.18 - $108.93 $368,526 - $541,164	4,968 Added 58.76%	13,423 $1.4 Million
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $2.13 Million - $2.9 Million	-33,741 Reduced 79.96%	8,455 $619,000
Q4 2019 Feb 14, 2020	BUY	$73.04 - $95.72 $501,492 - $657,213	6,866 Added 19.43%	42,196 $3.69 Million
Q3 2019 Nov 14, 2019	BUY	$72.82 - $86.52 $2.57 Million - $3.06 Million	35,330 New	35,330 $2.62 Million
Q2 2019 Aug 14, 2019	SELL	$73.52 - $88.7 $1.18 Million - $1.43 Million	-16,096 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$63.56 - $88.17 $2.78 Million - $3.86 Million	-43,759 Reduced 73.11%	16,096 $1.38 Million
Q4 2018 Feb 14, 2019	SELL	$58.5 - $69.94 $1.99 Million - $2.38 Million	-34,008 Reduced 36.23%	59,855 $3.81 Million
Q3 2018 Nov 14, 2018	BUY	$61.75 - $74.23 $2.76 Million - $3.32 Million	44,776 Added 91.22%	93,863 $6.48 Million
Q2 2018 Aug 14, 2018	BUY	$60.85 - $83.98 $1.03 Million - $1.42 Million	16,889 Added 52.45%	49,087 $3.29 Million
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $2.09 Million - $2.54 Million	25,192 Added 359.58%	32,198 $2.68 Million
Q4 2017 Feb 14, 2018	SELL	$93.56 - $116.6 $1.02 Million - $1.28 Million	-10,937 Reduced 60.95%	7,006 $664,000
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $1.96 Million - $2.48 Million	17,943	17,943 $2.1 Million

Others Institutions Holding INCY

# of Institutions

706

Shares Held

189M

Call Options Held

909K

Put Options Held

489K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account